LE180802 | Macular Degeneration Study


Help Medical Researchers

GET PAID 1600!

Enjoy Free WiFi & Food

APPLY NOW

Help us trial a new treatment for dry age-related macular degeneration (AMD) and juvenile onset macular degeneration, known as Stargardt disease (STGD).  Remuneration is based on completion of the in-house stay and all follow-up appointments.

Macular degeneration is the leading cause of major vision loss in Australia and can affect the ability to read, drive, recognise faces and perform activities that require detailed vision. Participating in this trial means you’ll be supporting world leading research into treatment for this condition. There are currently no approved treatments available for dry AMD or SGTD. 

Schedule

5 day in-house stay

Inclusion Criteria

  • Healthy Males and Females, aged between 18 and 65
  • Females must be of Non-Childbearing Potential (either Surgically Sterile or Postmenopausal)
  • Body Mass Index (BMI) between 18 – 30 kg/m2
  • Must be free from any clinically significant illness or disease
  • Participants must be non-smokers (Have not used any nicotine containing products in the last 28 days)
  • Participants must not have a history any severe reactions to medications
  • Participants must not have a history of Retinal Macular Edema or Stargardt Disease
APPLY NOW
NEXT

Spots are limited. Find out if you qualify today!

1 Appointment

1 phone call

Cohort In-House Phone Call Appointment
Check-In Day-1 Dosing Day 1 Check-Out Day 4 Day 6 Day 8
1.1 14-Jan-19 15-Jan-19 18-Jan-19 20-Jan-19 22-Jan-19
1.2 15-Jan-19 16-Jan-19 19-Jan-19 21-Jan-19 23-Jan-19
1.3 16-Jan-19 17-Jan-19 20-Jan-19 22-Jan-19 24-Jan-19

On Hold!

Fix the following errors:
Hide